Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone
暂无分享,去创建一个
Cheryl D. DiCarlo | Ronald L. Seaman | M. Chesselet | R. Seaman | P. Fernagut | Chunni Zhu | S. Fleming | C. Dicarlo | Pierre-Olivier Fernagut | Marie-Françoise Chesselet | Sheila M. Fleming | Chunni Zhu | Arpesh Mehta | A. Mehta
[1] H. Checkoway,et al. Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.
[2] J. Langston,et al. Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat , 2002, Neurobiology of Disease.
[3] M. Zigmond,et al. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. , 1984, Archives of neurology.
[4] G Fiskum,et al. Mitochondria in Neurodegeneration: Acute Ischemia and Chronic Neurodegenerative Diseases , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] Jean Féger,et al. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.
[6] M. Horne,et al. Axonal sprouting following lesions of the rat substantia nigra , 2000, Neuroscience.
[7] S. Haber,et al. Striatal Responses to Partial Dopaminergic Lesion: Evidence for Compensatory Sprouting , 2000, The Journal of Neuroscience.
[8] B. Liu,et al. Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease , 2003, The Journal of Neuroscience.
[9] M. Beal,et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Björklund,et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[11] Joseph P Huston,et al. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.
[12] J. Nobrega,et al. Brain Cytochrome Oxidase in Alzheimer's Disease , 1992, Journal of neurochemistry.
[13] Robert Hill,et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.
[14] I. Silver,et al. Methylmalonate toxicity in primary neuronal cultures , 1998, Neuroscience.
[15] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[16] D. Higgins,et al. In Vivo Labeling of Mitochondrial Complex I (NADH:UbiquinoneOxidoreductase) in Rat Brain Using [3H]Dihydrorotenone , 2000, Journal of neurochemistry.
[17] J. Schulz,et al. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.
[18] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[19] S. Wachtel,et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions , 1999, Neuroscience.
[20] T. Schallert,et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury , 2000, Neuropharmacology.
[21] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[22] R. Duvoisin,et al. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.
[23] B. Ritz,et al. Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.
[24] E. Love,et al. Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.
[25] Todd B. Sherer,et al. Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.
[26] C. Hertzman,et al. A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.
[27] T. Robinson,et al. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. , 1990, Canadian journal of psychology.
[28] T. Robinson,et al. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[29] J. M. Ree,et al. Behavioural changes after different stress paradigms: prepulse inhibition increased after physical, but not emotional stress , 2003, European Neuropsychopharmacology.
[30] R. Gross,et al. 3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms , 1998, Neuroscience.
[31] M. Chesselet,et al. Toxicity of Dopamine to Striatal Neurons In Vitro and Potentiation of Cell Death by a Mitochondrial Inhibitor , 1998, Journal of neurochemistry.
[32] Todd B. Sherer,et al. Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.
[33] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[34] M. Beal,et al. Mitochondria in Neurodegeneration: Bioenergetic Function in Cell Life and Death , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] B. Liu,et al. Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.
[36] R. Schwarting,et al. Evidence for a Dissociation between MPTP Toxicity and Tyrosinase Activity Based on Congenic Mouse Strain Susceptibility , 2001, Experimental Neurology.
[37] W. Schmidt,et al. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.
[38] T. Montine,et al. Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction , 2003, Journal of neurochemistry.
[39] R. Gainetdinov,et al. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[41] G. Kreutzberg. Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.
[42] M. Zigmond,et al. Forced Limb-Use Effects on the Behavioral and Neurochemical Effects of 6-Hydroxydopamine , 2001, The Journal of Neuroscience.
[43] Bin Liu,et al. Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.
[44] Bertrand Bloch,et al. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter , 1999, The European journal of neuroscience.
[45] Shelley R. Winn,et al. Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms , 1995, Experimental Neurology.
[46] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[47] T. Schallert,et al. A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia , 1992, Journal of Neural Transplantation & Plasticity.
[48] S. Rapoport,et al. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. , 1994, Brain research. Molecular brain research.
[49] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[50] M. Zigmond,et al. Forced Nonuse in Unilateral Parkinsonian Rats Exacerbates Injury , 2002, The Journal of Neuroscience.
[51] P. Teitelbaum,et al. Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of parkinsonism , 1979, Experimental Neurology.
[52] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[53] R. Wightman,et al. Profound neuronal plasticity in response to inactivation of the dopamine transporter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Sanberg,et al. Central Nervous System Diseases , 2000, Contemporary Neuroscience.